## References

1.  Russell M.Hagan, ArthurButler, JuliaM.Hill, Christopher C. Jordan, Simon J. Ireland, and Michael B. Tyers. Effect of the 5-HT3 receptor antagonist, GR38032f, on responses to injection of a neurokinin agonist into the ventral tegmental area of the rat brain. *European Journal of Pharmacology*, 138(2):303--305, 1987.

2.  Kathleen A. Grant and James E. Barrett. Blockade of the discriminative stimulus effects of ethanol with 5-HT3 receptor antagonists. *Psychopharmacology*, 104(4):451--456, 1991.

3.  B. A. Johnson, G. M. Campling, P. Griffiths, and P. J. Cowen. Attenuation of some alcohol-induced mood changes and the desire to drink by 5-HT3 receptor blockade: a preliminary study in healthy male volunteers. *Psychopharmacology*, 112(1):142--144, 1993.

4.  B. A. Johnson, J. D. Roache, M. A. Javors, C. C. DiClemente, C. R. Cloninger, T. J. Prihoda, P. S. Bordnick, N. Ait-Daoud, and J. Hensler. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: A randomized controlled trial. *JAMA*, 284(8):963--971, 2000.

5.  Henry R. Kranzler, Amira Pierucci-Lagha, Richard Feinn, and Carlos Hernandez-Avila. Effects of ondansetron in early- versus late-onset alcoholics: A prospective, open-label study:. *Alcoholism: Clinical & Experimental Research*, 27(7):1150--1155, 2003.

6.  Vijoy K Varma, Debasish Basu, Anil Malhotra, Avneet Sharma, and Surendra K Mattoo. Correlates of earlyand late-onset alcohol dependence. *Addictive behaviors*, 19(6):609--619, 1994.

7.  Nassima Ait-Daoud, John D Roache, Michael A Dawes, Lei Liu, Xin-Qun Wang, Martin A Javors, Chamindi Seneviratne, and Bankole A Johnson. Can serotonin transporter genotype predict craving in alcoholism? *Alcoholism: Clinical and Experimental Research*, 33(8):1329--1335, 2009.

8.  Edward M. Sellers, Tony Toneatto, Myroslava K. Romach, Gail R. Somer, Linda C. Sobell, and Mark B. Sobell. Clinical efficacy of the 5-HT3 antagonist ondansetron in alcohol abuse and dependence. *Alcoholism: Clinical and Experimental Research*, 18(4):879--885, 1994.

9.  Bankole A. Johnson, Nassima Ait-Daoud, and Thomas J. Prihoda. Combining ondansetron and naltrexone effectively treats biologically predisposed alcoholics: From hypotheses to preliminary clinical evidence. *Alcoholism: Clinical and Experimental Research*, 24(5):737--742, 2000.

10. N. Ait-Daoud, B. A. Johnson, T. J. Prihoda, and I. D. Hargita. Combining ondansetron and naltrexone reduces craving among biologically predisposed alcoholics: preliminary clinical evidence. *Psychopharmacology*, 154(1):23--27, 2001.

11. Nassima Ait-Daoud, Bankole A. Johnson, Martin Javors, John D. Roache, and Nursen A. Zanca. Combining ondansetron and naltrexone treats biological alcoholics: Corroboration of self-reported drinking by serum carbohydrate deficient transferrin, a biomarker. *Alcoholism: Clinical and Experimental Research*, 25(6):847--849, 2001.

12. Bankole A. Johnson, John D. Roache, Nassima AitDaoud, Nursen A. Zanca, and Madeline Velazquez. Ondansetronreducesthecravingofbiologicallypredisposed alcoholics. *Psychopharmacology*, 160(4):408-- 413, 2002.

13. Bankole A. Johnson, Nassima Ait-Daoud, Jennie Z. Ma, and Yanmei Wang. Ondansetron reduces mood disturbance among biologically predisposed, alcoholdependent individuals:. *Alcoholism: Clinical & Experimental Research*, 27(11):1773--1779, 2003.

14. John D. Roache, Yanmei Wang, Nassima Ait-Daoud, and Bankole A. Johnson. Prediction of serotonergic treatment efficacy using age of onset and type a/b typologies of alcoholism. *Alcoholism, Clinical and Experimental Research*, 32(8):1502--1512, 2008.

15. Michael A. Dawes, Bankole A. Johnson, Nassima AitDaoud, Jennie Z. Ma, and Jack R. Cornelius. A prospective, open-label trial of ondansetron in adolescents with alcohol dependence. *Addictive Behaviors*, 30(6):1077--1085, 2005.

16. Michael A. Dawes, Bankole A. Johnson, Jennie Z. Ma, Nassima Ait-Daoud, Suzanne E. Thomas, and Jack R. Cornelius. Reductions in and relations between \"craving\" and drinking in a prospective, open-label trial of ondansetron in adolescents with alcohol dependence. *Addictive Behaviors*, 30(9):1630--1637, 2005.

17. Hugh Myrick, Raymond F Anton, Xingbao Li, Scott Henderson, Patrick K Randall, and Konstantin Voronin. Effect of naltrexone and ondansetron on alcohol cue--induced activation of the ventral striatum in alcohol-dependent people. *Archives of general psychiatry*, 65(4):466--475, 2008.

18. George A. Kenna, William H. Zywiak, John E. McGeary, Lorenzo Leggio, Chinatsu McGeary, Shirley Wang, Andrea Grenga, and Robert M. Swift. A within-group design of nontreatment seeking 5HTTLPR genotyped alcohol-dependent subjects receiving ondansetron and sertraline. *Alcoholism, Clinical and Experimental Research*, 33(2):315--323, 2009.

19. Bankole A. Johnson, Nassima Ait-Daoud, Chamindi Seneviratne, John D. Roache, Martin A. Javors, Xin-Qun Wang, Lei Liu, J. Kim Penberthy, Carlo C. DiClemente, and Ming D. Li. Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking. *The American Journal of Psychiatry*, 168(3):265--275, 2011.

20. Bankole A. Johnson, Chamindi Seneviratne, Xin-Qun Wang, Nassima Ait-Daoud, and Ming D. Li. Determination of genotype combinations that can predict the outcome of the treatment of alcohol dependence using the 5-HT(3) antagonist ondansetron. *The American Journal of Psychiatry*, 170(9):1020--1031, 2013.

21. Chamindi Seneviratne and Bankole A. Johnson. Serotonin transporter genomic biomarker for quantitative assessment of ondansetron treatment response in alcoholics. *Frontiers in Psychiatry*, 3:23, 2012.

22. Jue Hou, Chamindi Seneviratne, Xiaogang Su, Jeremy Taylor, Bankole Johnson, Xin-Qun Wang, Heping Zhang, Henry R. Kranzler, Joseph Kang, and Lei Liu. Subgroup identification in personalized treatment of alcohol dependence. *Alcoholism, Clinical and Experimental Research*, 39(7):1253--1259, 2015.

23. João Maria Corrêa Filho and Danilo Antonio Baltieri. A pilot study of full-dose ondansetron to treat heavydrinking men withdrawing from alcohol in brazil. *Addictive Behaviors*, 38(4):2044--2051, 2013.

24. George A. Kenna, William H. Zywiak, Robert M. Swift, John E. McGeary, James S. Clifford, Jessica R. Shoaff, CynthiaVuittonet, SamuelFricchione, Michael Brickley, Kayla Beaucage, Carolina L. Haass-Koffler, and Lorenzo Leggio. Ondansetron reduces naturalistic drinking in nontreatment-seeking alcohol-dependent individuals with the LL 5'-HTTLPR genotype: a laboratory study. *Alcoholism, Clinical and Experimental Research*, 38(6):1567--1574, 2014.

25. George A. Kenna, William H. Zywiak, Robert M. Swift, John E. McGeary, James S. Clifford, Jessica R. Shoaff, Samuel Fricchione, Michael Brickley, Kayla Beaucage, Carolina L. Haass-Koffler, and Lorenzo Leggio. Ondansetron and sertraline may interact with 5-HTTLPR and DRD4 polymorphisms to reduce drinking in non-treatment seeking alcohol-dependent women: Exploratory findings. *Alcohol*, 48(6):515-- 522, 2014.

26. E. Sherwood Brown, Meagan McArdle, Jayme Palka, Collette Bice, Elena Ivleva, Alyson Nakamura, Markey McNutt, Zena Patel, Traci Holmes, and Shane Tipton. A randomized, double-blind, placebo-controlled proof-of-concept study of ondansetron for bipolar and related disorders and alcohol use disorder. *European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology*, 43:92-- 101, 2021.

27. Jonathan AC Sterne, Jelena Savović, Matthew J Page, Roy G Elbers, Natalie S Blencowe, Isabelle Boutron, Christopher J Cates, Hung-Yuan Cheng, Mark S Corbett, Sandra M Eldridge, et al. Rob 2: a revised tool for assessing risk of bias in randomised trials. *bmj*, 366:l4898, 2019.

28. Luke A. McGuinness and Julian P. T. Higgins. Risk-ofbias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments. *Research Synthesis Methods*, 12(1):55--61, 2021.

29. J Peterson, V Welch, M Losos, PJOOHRI Tugwell, et al. The newcastle-ottawa scale (nos) for assessing the quality of nonrandomised studies in meta-analyses. *Ottawa: Ottawa Hospital Research Institute*, pages 1-- 12, 2011.

30. B. A. Johnson, C. R. Cloninger, J. D. Roache, P. S. Bordnick, and P. Ruiz. Age of onset as a discriminator between alcoholic subtypes in a treatment-seeking outpatient population. *The American Journal on Addictions*, 9(1):17--27, 2000.

31. Linda C Sobell and Mark B Sobell. *Timeline followback: user's guide*. Addiction Research Foundation, 1996.

32. Raymond F Anton, Darlene H Moak, and Patricia K Latham. The obsessive compulsive drinking scale: A new method of assessing outcome in alcoholism treatment studies. *Archives of general psychiatry*, 53(3):225--231, 1996.

33. Douglas McNair, Maurice Lorr, and Leo Droppleman. Profile of mood states (poms). 1989.

34. Thomas F. Babor, Michael Hofmann, Frances K. DelBoca, Victor Hesselbrock, Roger E. Meyer, Zelig S. Dolinsky, and Bruce Rounsaville. Types of Alcoholics, I:EvidenceforanEmpiricallyDerivedTypologyBased on Indicators of Vulnerability and Severity. *Archives of General Psychiatry*, 49(8):599--608, 1992.

35. Mark D. Litt, Thomas F. Babor, Frances K. DelBoca, Ronald M. Kadden, and Ned L. Cooney. Types of Alcoholics, II: Application of an Empirically Derived Typology to Treatment Matching. *Archives of General Psychiatry*, 49(8):609--614, 1992.

36. C Robert Cloninger. A systematic method for clinical descriptionandclassificationofpersonalityvariants: A proposal. *Archives of general psychiatry*, 44(6):573-- 588, 1987.

37. Isabelle E. Bauer, David P. Graham, Jair C. Soares, and David A. Nielsen. Serotonergic gene variation in substance use pharmacotherapy: a systematic review. *Pharmacogenomics*, 16(11):1307--1314, 2015.

38. Andrew C. Naglich, Austin Lin, Sidarth Wakhlu, and Bryon H. Adinoff. Systematic Review of Combined Pharmacotherapy for the Treatment of Alcohol Use Disorder in Patients Without Comorbid Conditions. *CNS drugs*, 32(1):13--31, 2018.

39. Anita Cservenka, Megan M. Yardley, and Lara A. Ray. Review: Pharmacogenetics of alcoholism treatment: Implications of ethnic diversity. *The American Journal on Addictions*, 26(5):516--525, 2017.

40. Sari Castrén, Niklas Mäkelä, and Hannu Alho. Selecting an appropriate alcohol pharmacotherapy: review of recent findings. *Current Opinion in Psychiatry*, 32(4):266--274, 2019.

41. Balaji Bharadwaj, Nivedhitha Selvakumar, and Pooja Patnaik Kuppili. Pharmacotherapy for relapse prevention of alcohol use disorder in the Indian setting: A systematic review. *Industrial Psychiatry Journal*, 27(2):163--171, 2018.

42. Miles D. Thompson and George A. Kenna. Variation in the Serotonin Transporter Gene and Alcoholism: Risk and Response to Pharmacotherapy. *Alcohol and Alcoholism (Oxford, Oxfordshire)*, 51(2):164--171, 2016.
